Outcomes of pediatric and adult patients with relapsed/refractory cortical (CD1a+) T-cell acute lymphoblastic leukemia. The Spanish experience from SEHOP and PETHEMA groups


Por: Rivera-Pérez, C, Morgades, M, Alonso-Saladrigues, A, Montesinos, P, Murciano, T, Gil, C, Adán, R, Esteve, J, Fuentes, C, Amigo, ML, González-Martínez, B, Coll, R, Dapena, JL, De Llano, MPQ, Fuster, JL, García-Cadenas, I, Tasso, M, Barba, P, Rives, S, Ribera, JM

Publicada: 24 mar 2026
Resumen:
Patients with relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) have very poor prognosis. CAR T-cell therapy is being explored in these patients with encouraging results. Specifically, CD1a-directed CAR T-cells are being explored in clinical trials to treat cortical T-ALL (CD1a+), but there are no data on outcome in this subgroup of patients before this therapy. This retrospective, observational study aimed to describe the characteristics and outcomes of patients with R/R CD1a + T-ALL. We included pediatric and adult patients diagnosed with R/R CD1a + T-ALL in 25 sites of Spain between March 2006 and May 2022. The primary outcome of the study was overall survival (OS). Forty-three patients, 28 adults and 15 children, with R/R CD1a + T-ALL were included. Median (range) age at inclusion was 24 years (5-57), and 82.5% were male. After a median (range) follow-up of 7.0 years (5.1-13.6), 6 (14.0%) patients were alive and in complete remission (CR) and 37 (86.0%) had died. Five-year OS was 16% (95% CI; 7-29%). Bone marrow relapse, an interval < 12 months between first CR and relapse, and lack of allogeneic hematopoietic stem cell transplantation during salvage treatment were associated with worse OS. Our results confirm that patients with R/R CD1a + T-ALL have a very poor prognosis, highlighting the need for new treatment alternatives in these patients.

Filiaciones:
Rivera-Pérez, C:
 Hosp St Joan Deu Barcelona, Pediat Canc Ctr Barcelona PCCB, Stem Cell Transplant Dept, Barcelona, Spain

 Univ Barcelona, Fac Med, Barcelona, Spain

Morgades, M:
 Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Clin Hematol Dept, Badalona, Spain

Alonso-Saladrigues, A:
 Univ Barcelona, Fac Med, Barcelona, Spain

 Hosp St Joan Deu Barcelona, Pediat Canc Ctr Barcelona PCCB, Leukemia & Lymphoma Dept, Barcelona, Spain

 Inst Recerca St Joan Deu, Barcelona, Spain

Montesinos, P:
 Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain

Murciano, T:
 Hosp Univ Vall dHebron, Pediat Oncol & Hematol Dept, Barcelona, Spain

 Vall dHebron Res Inst VHIR, Barcelona, Spain

Gil, C:
 Hosp Gen Univ Dr Balmis, Hematol Dept, Hosp Gen Universitari Dr, Alacant, Spain

Adán, R:
 Hosp Univ Cruces, Pediat Hematol & Oncol Unit, Baracaldo, Spain

 Biobizkaia Hlth Res Inst, Pediat Oncol Res Grp, Baracaldo, Spain

Esteve, J:
 Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain

 Univ Barcelona, IDIBAPS, Barcelona, Spain

Fuentes, C:
 Hosp Univ & Politecn La Fe, Pediat Oncol & Hematol Dept, Valencia, Spain

Amigo, ML:
 Hosp Gen Univ Morales Meseguer, Hematol Dept, Murcia, Spain

González-Martínez, B:
 Hosp Univ La Paz, Pediat Hematol & Oncol Dept, Madrid, Spain

Coll, R:
 Hosp Univ Dr Josep Trueta, Inst Catala Oncol, Hematol Dept, Hosp Universitari Dr, Girona, Spain

Dapena, JL:
 Hosp St Joan Deu Barcelona, Pediat Canc Ctr Barcelona PCCB, Stem Cell Transplant Dept, Barcelona, Spain

De Llano, MPQ:
 Hosp Univ Virgen Victoria, Hematol Dept, Malaga, Spain

Fuster, JL:
 Hosp Clin Univ Virgen Arrixaca Palmar, Murcia, Spain

 Inst Murciano Invest Biosanit IMIB, El Palmar, Spain

García-Cadenas, I:
 Hosp Santa Creu & Sant Pau, Hematol Dept, Barcelona, Spain

Tasso, M:
 Hosp Gen Univ Dr Balmis, Pediat Oncol & Hematol Dept, Alacant, Spain

 ISABIAL, Alacant, Spain

Barba, P:
 Hosp Univ Vall dHebron, Hematol Dept, Barcelona, Spain

Rives, S:
 Hosp St Joan Deu Barcelona, Pediat Canc Ctr Barcelona PCCB, Leukemia & Lymphoma Dept, Barcelona, Spain

 Inst Recerca St Joan Deu, Barcelona, Spain

Ribera, JM:
 Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Clin Hematol Dept, Badalona, Spain

 Josep Carreras Leukemia Res Inst, Badalona, Spain
ISSN: 09395555





ANNALS OF HEMATOLOGY
Editorial
SPRINGER, ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES, Alemania
Tipo de documento: Article
Volumen: 105 Número: 4
Páginas:
WOS Id: 001721929700001
ID de PubMed: 41874722
imagen Green Submitted, gold

MÉTRICAS